It’s only fair to share… Nivegacetor CAS 2443487-67-8 MF C23H25F2N7O2 MW 469.5 g/mol (R)-7-(3,5-difluorophenoxy)-N-((1R,5S,8s)-3-(6-methoxypyridazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine and (S)-7-(3,5-difluorophenoxy)-N-((1R,5S,8s)-3-(6-methoxypyridazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine (7R)-7-(3,5-difluorophenoxy)-N-[(1S,5R)-3-(6-methoxypyridazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine (7R)-7-(3,5-difluorophenoxy)-N-[(1R,5S,8s)-3-(6-methoxypyridazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro5H-pyrrolo[1,2-b][1,2,4]triazol-2-aminegamma secretase modulator, SF4J7MVJ56, RG 6289, RG-6289, ROCHE, ALZHIEMER, Nivegacetor is a potent γ-secretase modulator. Nivegacetor is an investigational gamma-secretase modulator being developed by Roche for the treatment of Alzheimer’s disease.[1] The compound is also known by its development code name RG6289 and represents a second-generation gamma-secretase modulator designed to …
Category «alzheimers»
J-147
It’s only fair to share… J-147 N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N’-[(E)-(3-methoxyphenyl)methylene]acetohydrazide Molecular FormulaC18H17F3N2O2 Average mass350.335 Da 2,2,2-trifluoroacetic acid-1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(1E)-(3-methoxyphenyl)methylene]hydrazide N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N’-[(E)-(3-methoxyphenyl)methylene]acetohydrazide [1146963-51-0] 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide, 2,2,2-trifluoro-acetic acid 1146963-51-0 [RN] DOUBLE BOND GEOMETRY UNSPECIFIED 1807913-16-1 [RN] AS PER https://chem.nlm.nih.gov/chemidplus/sid/1807913161 E FORM FDA UNII Z41H3C5BT9 Abrexa Pharmaceuticals, Dementia, Alzheimer’s type, PHASE1 Blanchette Rockefeller Neurosci Inst (Originator) Salk Institute for Biological Studies (Originator) Abrexa Pharmaceuticals is …
CT-1812
It’s only fair to share… CT-1812 Elayta Condition(s): Alzheimer’s Disease U.S. FDA Status: Alzheimer’s Disease (Phase 2) Company: Cognition Therapeutics Inc. CAS: 1802632-22-9 Chemical Formula: C24H33NO4S Molecular Weight: 431.591 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol Phenol, 4-[3-[1,3-dihydro-5-(methylsulfonyl)-2H-isoindol-2-yl]-3-methylbutyl]-2-(1,1-dimethylethoxy)- Originator Cognition Therapeutics Class Antidementias; Neuroprotectants; Nootropics; Small molecules Mechanism of Action Sigma-2 receptor antagonists Phase II Alzheimer’s disease Phase I Cognition disorders 21 Feb 2019 Cognition Therapeutics receives patent for …